Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 6, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a type of cancer called Acute Myeloid Leukemia (AML) in children, teenagers, and young adults. AML can be difficult to treat, and many patients may experience a relapse, so researchers want to learn more about the genetic factors that contribute to this. The study aims to collect samples from patients’ leukemia cells to identify genetic changes that may lead to treatment resistance and predict the risk of relapse. Additionally, the trial will look at how certain cells in the bone marrow interact with treatment and test how different drugs work on the leukemia cells.

To participate in this trial, individuals aged 0 to 25 who have been newly diagnosed with AML, have had a relapse, or have a genetic predisposition to develop AML may be eligible. Participants will need their parents’ consent if they are under 18, while those over 18 can provide their own consent. During the study, patients can expect to provide samples as part of their regular care, and they will help researchers gain valuable insights that could improve future treatments for AML. It's important to note that individuals with certain conditions, such as chronic myeloid leukemia or those who are pregnant or breastfeeding, cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 0-25 years old
• • Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or
• • Relapsed or refractory AML or
• • Patients with genetic predisposition to develop AML or
• • Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care
• • Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over.
• Exclusion Criteria:
• • Refuse to participate
• • Chronic myeloid leukemia (CML)
• • Lack of health insurance (French social security)
• • Under protection (tutelle, curatelle or sauvegarde de justice)
• • Pregnancy or breastfeeding